Key Highlights

  • Splash Beverage Group granted a 15% royalty to the Licensor on net revenue generated from sales of the Licensed Product.
  • C/M Capital Partners committed to invest at least $1 million to support the company's commercialization efforts.

Introduction Overview

Splash Beverage Group Inc. (NYSE American: SBEV) has entered into an Exclusive License Agreement with Argent Biopharma Limited, acquiring the rights to the pharmaceutical product CannEpil. This product is designed for the treatment of epilepsy and related neurological conditions in humans. The healthcare sector is expected to benefit from this development.

License Agreement Details

The License Agreement grants Splash Beverage Group Inc. The rights to CannEpil, a pharmaceutical product that aims to address complex seizure disorders. The company has ambitions to achieve important development milestones, including initiating a Phase I clinical trial within 24 months.

The pharmaceutical industry is expected to see significant growth with the development of new treatments.

Royalty Payments

Splash Beverage Group Inc. Granted a 15% royalty to the Licensor on net revenue generated from sales of the Licensed Product. This royalty payment will be made until the longer of 10 years following the first commercial sale in each country or the expiration of the last-to-expire patent claiming the Licensed Product in each country.

The royalty payment structure is a common practice in the healthcare industry.

Investment Commitment

C/M Capital Partners committed to invest at least $1 million to support Splash Beverage Group Inc.'s commercialization efforts for the Licensed Product. The company also agreed to pay C/M a sales bonus of $1 million upon achieving $5 million in cumulative net revenue. This investment commitment is expected to boost the company's financial performance.

Series D Convertible Preferred Stock

Splash Beverage Group Inc. This stock issuance is part of the consideration for entering into the License Agreement. The company's capital structure is expected to be strengthened by this move.

Regulatory Approval

Splash Beverage Group Inc. Will need to obtain regulatory approval to commercialize the Licensed Product in the United States. The company will need to comply with extensive regulations, including clinical testing, before it can market the product in applicable jurisdictions.

The regulatory environment is a critical factor in the pharmaceutical industry.

Future Prospects

The acquisition of the license for CannEpil is expected to have a positive impact on Splash Beverage Group Inc.'s future prospects. The company's ability to develop and commercialize new products will be crucial to its success in the healthcare sector. The pharmaceutical product market is highly competitive, and the company will need to navigate this landscape effectively.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.